Full Press Release Details
SAN DIEGO, Feb. 6, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on NASDAQ (MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it will report its year end 2006 financial results on Thursday, February 15, 2007, after the close of U.S. financial markets. Following the announcement, company management will host a conference call to discuss the results and provide a general corporate update and 2007 financial guidance.
DATE: February 15, 2007
TIME: 1:30 pm PT, 4:30 pm ET
DOMESTIC DIAL-IN: (888) 208-1815
INTERNATIONAL DIAL-IN: (719) 457-2656
(Please dial-in approximately 10 minutes before the call is scheduled
A replay of the call will be available through February 21st by
dialing (888) 203-1112 or (719) 457-0820, and entering conference ID
A live audio Webcast will be available at: investors.medicinova.com
MediciNova, Inc. is a biopharmaceutical company focused on accelerating the global development and commercialization of innovative pharmaceutical products. MediciNova's pipeline, which includes six compounds in clinical testing, targets a variety of prevalent medical conditions, including asthma, multiple sclerosis, status asthmaticus, interstitial cystitis, solid tumors, Generalized Anxiety Disorder, preterm labor, urinary incontinence and thrombotic disorders. For more information on MediciNova, Inc., please visit www.medicinova.com.
The MediciNova, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3135
This press release may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding clinical trials supporting efficacy of one of our product candidates as well as the potential novelty of that candidate as a treatment for disease. These statements are based on certain assumptions made by the Company's management that are believed to be reasonable at the time. Such statements are subject to a number of risks and uncertainties, many of which are beyond the control of the Company, including the results of clinical studies and other risks and uncertainties, including those described in the Company's filings with the Securities and Exchange Commission. These assumptions, risks and uncertainties could cause the Company's actual results to differ materially from those implied or expressed by the forward-looking statements.